Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07515014 |
| Consolidated Lead Sponsor | Eisai |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 256 participants (ESTIMATED) |
| Registered Start Date | 2026-03-31 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Guangdong Provincial People's Hospital | Guangzhou, China | Open Hospital Dossier -> |
| The first affiliated hospital of Guangxi Medical University | Nanning, China | Open Hospital Dossier -> |
| The affiliated hospital of Guizhou medical university | Guiyang, China | Open Hospital Dossier -> |
| The Second Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.